A silent cost surge is tightening its grip on Kenya’s healthcare system. Dialysis, a life-sustaining procedure, is becoming more expensive to maintain. The price of essential consumables has risen sharply. For thousands of patients, this is not an abstract statistic. It is a daily burden that is growing heavier. 

Recent reporting by Business Daily Africa shows that the cost of dialysis consumables has increased by an average of 30 per cent over the past three years. This rise directly affects treatment costs. Consumables are not optional. They are central to every dialysis session. Without them, the process cannot happen. 

Currently, Kenya has more than 8,000 patients undergoing dialysis. Each of them depends on regular sessions to survive. Many require treatment multiple times a week, so even small price increases accumulate quickly. A 30 per cent jump is therefore significant. It translates into sustained financial strain over time. 

The Cost Chain Reaction 

Why does this increase matter so much? Because dialysis is already expensive. Consumables form a recurring cost. Unlike machines, which are capital investments, these supplies must be purchased continuously. Their prices are sensitive to global supply chains, import costs, and currency fluctuations. When prices rise, hospitals pass the cost along. Patients and insurers absorb the impact. 

This creates a chain reaction. Higher consumable costs push up the overall price of dialysis sessions. Insurance providers face higher claims. In response, they may adjust premiums or limit coverage. Patients who rely on out-of-pocket payments feel the pressure immediately. Those on limited insurance cover may find gaps widening. 

Existing data show that dialysis is among the more costly long-term treatments. Even where government entities such as the Social Health Authority (SHA) offer support, coverage limits may not fully absorb rising input costs. This leaves patients exposed. The increase in consumables pricing, therefore, risks undermining access. 

A System Under Strain 

The implications go beyond individual patients. Healthcare providers must balance cost recovery with accessibility. If prices rise too high, fewer patients can afford consistent treatment. This creates clinical risks. Missed or delayed dialysis sessions can lead to severe complications. 

At the same time, suppliers and facilities face their own pressures. Import-dependent medical supplies are vulnerable to global price shifts. Currency depreciation can worsen the situation. Without policy intervention or cost controls, the upward trend may persist. 

The question is no longer whether costs are rising. That is established. The deeper concern is sustainability. Can the system continue to absorb these increases without limiting access? 

For now, the answer remains uncertain. What is clear is that dialysis patients are caught in the middle. And the cost of staying alive is steadily climbing.